Redefining AAV manufacturing: a case study on improving AAV2 and AAV9 titers & percent full capsids while reducing production costs

Devan Puhl is a Senior Scientist in Process Development at Artis BioSolutions, where she has been part of the team for over four years. At Artis, she leads the upstream development team, supporting the company's diverse cell and gene therapy programs, optimizing scalable processes, and enabling their transfer to Artis's on-site cGMP facility in Watertown, MA. Devan holds a PhD in Biomedical Engineering from Rensselaer Polytechnic Institute, where her doctoral research focused on drug and gene delivery from biomaterials for nerve repair. She was a National Science Foundation Graduate Research Fellow and a New York State Spinal Cord Injury Research Board Fellowship Awardee. Her findings have been published in multiple peer-reviewed journals, including Nature Communications and Acta Biomaterialia.

Leisha Kopp is a Senior Field Applications Scientist at Mirus Bio, a company committed to equipping biopharmaceutical innovators with next generation transfection solutions for all cell culture applications. Leisha has 20 years of molecular biology and mammalian cell culture experience in industrial labs and has worked extensively with an array of primary and immortalized mammalian cells. Her combined bench and biopharma knowledge enables support of scientists in all stages of the drug discovery process to develop optimized and scalable processes that deliver complex therapies to patients more quickly. Leisha is a graduate of the University of Wisconsin-Madison, with key interests in viral vector manufacturing and gene therapy.